Approval · Notice of Compliance 30820 · 2023
PERSERIS: Notice of Compliance 30820
Issued May 25, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30820
- Date
- May 25, 2023
- Company
- Hls Therapeutics IncEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of an alternate injection site on the back of the upper arm. Revisions to the syringe labels to include both Canadian and US information. Update to the Product Monograph (PM) to Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PERSERIS | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 90 MG per SYR
- RISPERIDONE 120 MG per SYR